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Abstract - Tumor necrosis factor (TNF) which exerts its effects through two different receptors known as TNF-R1 and 
TNF-R2, is a major proinflammatory cytokine involved in the pathogenesis of different types of tumors. We have investi-
gated whether polymorphisms in TNF-alpha (-308G>A), TNF receptor 1 (36A>G) and TNF receptor 2 (676T>G) genes 
modulate the susceptibility for oral squamous cell carcinomas (OSCCs) and basal cell carcinomas (BCCs) of the skin, two 
frequent types of head and neck cancers. Genotyping was done on 50 OSCC patients, 50 BCC patients and 60 healthy 
individuals, using PCR/RFLP. A significant difference in genotype and allele frequencies was found between patients and 
controls for the TNF-R2 polymorphism, in both OSCC and BCC. There was no statistically significant difference between 
patients and controls for TNF-alpha and TNF-R1 polymorphisms. Carriers of G allele had an approximately 2.5- and 
5-fold higher risk for OSCC and BCC, respectively, in the Serbian population.
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INTRODUCTION
Head and neck cancers are among the most com-
mon malignancies and their overall incidence, es-
pecially those of the larynx and the oral cavity, is 
increasing worldwide, in particular among young 
people (Parkin et al., 2005). Localizations of these 
malignancies include oral and nasal cavity, phar-
ynx, paranasal sinuses, larynx, salivary glands and 
sun-exposed areas of the skin of head and neck 
(Burtness, 2002). Squamous cell carcinomas of 
the oral cavity (OSCC) account for approximately 
500,000 new cases worldwide, making it the 6th 
most common cancer type (Parkin et al., 2005). 
OSCCs are considered aggressive tumors with 
marked tendency to recurrences and metastases. 
The overall 5-year survival rate is just 50% (van Oi-
jen and Slootweg, 2000). Almost 85% of patients 
with OSCC are alcohol or tobacco abusers, or both 
(Williams, 2000).
Basal cell carcinomas (BCCs) are nonmelanoma 
skin cancers that develop in sun-exposed areas and 
therefore a large proportion, around 74%, occurs in 
the head and neck (HNBCCs) region (Jung et al., 
2010). HNBCCs are non-aggressive tumors with 
slow growth and low recurrence rates (Ting et al., 
2005). Local destruction may occur if left untreated 
or incompletely removed (Ko et al., 1992).
Although there are many different factors and 
mechanisms involved in tumor pathogenesis and 
invasion, among others the increased expression of 
several cytokines has been observed during the de-
velopment of head and neck carcinomas (Woods et 
al., 1998). 
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Though TNF-alpha has a well-established an-
tineoplastic role, the dysregulation of gene expres-
sion in the TNF-TNF receptor superfamily has 
been involved in various human cancers, through 
the stimulation of DNA damage, angiogenesis, tu-
mor growth, invasion and metastasis (Mantovani, 
2005). 
TNF-alpha expression is influenced by polymor-
phisms in the TNF-alpha gene promoter (Raabe et 
al., 1998). A special emphasis has been put on the 
(-308G>A) polymorphism. Guanine at position -308 
defines the common TNF1 allele and adenine the 
less common TNF2 allele. The A allele of TNF-alpha 
at position -308 polymorphism has been associated 
with increased TNF-alpha production (Kroeger et 
al., 1997). TNF2 allele has been shown to correlate 
with unfavorable outcome in myeloid malignancies 
(Davies et al., 2000).
TNF-alpha exerts its effects via two members of 
the TNF receptor superfamily, tumor necrosis factor 
receptors 1 and 2 (TNF-R1, TNF-R2). The structural 
similarity between the two TNF receptors is limited 
to their extracellular domains (Tartaglia and Goed-
del, 1992). TNF-R1 has a role in cell death as well as 
in normal immune regulation, whilst TNF-R2 lacks 
a death domain (DD) and thus cannot stimulate 
the apoptotic process. However, TNF-R2 interfer-
ence with programmed-cell-death cannot be ruled 
out. The function of TNF-R2 should not be under-
estimated, particularly because this receptor shows 
a restricted but inducible expression (Carpentier 
et al., 2004). Functional SNPs in TNF-alpha recep-
tors genes have been described as well. Association 
studies dealing with polymorphisms in the genes 
responsible for the control of immune and inflam-
matory processes, in patients with head and neck 
tumors, are extremely scarce and mainly limited to 
Asian populations. This prompted us to examine the 
patterns of variation in three SNPs in the following 
candidate genes: TNF-alpha, TNF-receptor 1 and 
TNF-receptor 2, and to establish whether any of the 
polymorphisms may represent a risk factor for the 
development of two very frequent types of head and 
neck tumors, characterized by quite different clinical 
behavior, one aggressive (OSCC) and the other rela-
tively benign (BCC). 
MATERIALS AND METHODS
Patients
The study included 100 patients, 50 with OSCC (mean 
age 69 years, 35 males, 15 females) and 50 with BCC 
(mean age 73 years, 20 males, 30 females) treated at 
the Clinic of Maxillofacial Surgery, School of Den-
tistry, University of Belgrade, as well as 60 healthy 
individuals, age matched, all of Serbian ethnicities. 
The study protocol was approved by the institutional 
Ethical Committee. In the patients group, DNA was 
isolated from the tissue of histologically negative tu-
mor margins, whilst in the control group DNA was 
isolated from buccal swabs. For both isolations a 
QIAmp DNA Mini Kit (Qiagen,GmbH, Germany) 
was used, as recommended by the manufacturer. 
Genotyping
A polymerase chain reaction-restriction fragment 
length polymorphism (PCR-RFLP) technique was 
used to detect the TNF-alpha (-308G>A), TNF-R1 
(36A>G) and TNF-R2 (676T>G) substitution poly-
morphisms.
The region of the TNF-alpha gene containing 
the -308 position was amplified using the primers 
(0.25µM) forward: 5’-AGG CAA TAG GTT TTG 
AGG GCC AT-3’; and reverse: 5’-ACA CTC CCC 
ATC CTC CCT GCT-3’. A 117 bp PCR product was 
generated using the following amplification condi-
tions: 94˚C for 3 min, followed by 35 cycles at 94˚C 
for 60 s, 60˚C for 60 s and 72˚C for 60 s, with a final 
extension step at 72˚C for 10 min. NcoI restriction 
enzyme (MBI Fermentas, Lithuania) digestion was 
performed at 37˚C overnight (1 unit NcoI and 10 μl 
PCR products). The genotypes were then assessed by 
PAA gel electrophoresis. The fragments were as fol-
lows: 97 and 20 bp fragments in GG homozygous in-
dividuals, three fragments 117bp, 97bp and 20bp in 
GA heterozygous individuals and only single 117bp 
fragment in AA homozygous individuals. 
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The region of the TNF-R1 gene containing 
the +36 position was amplified using the primers 
(0.2µM) forward: 5’-GAC CCC AAA TGG GGG 
AGT GAG AGG-3’; reverse: 5’-ACC AGG CCC 
GGG CAG GAG AG-3’. A 183 bp PCR product was 
generated using the following amplification condi-
tions: 94˚C for 3 min, followed by 35 cycles at 94˚C 
for 60 s, 65˚C for 60 s and 72˚C for 60 s, with a final 
extension step at 72˚C for 10 min. Restriction analy-
sis was performed using the Mspa1I enzyme (New 
England BioLabs Ltd.). Digestion was performed at 
37˚C overnight (1 unit Mspa1I and 10 μl PCR prod-
ucts). The genotypes were then assessed by PAA gel 
electrophoresis. The fragments were as follows: 183 
bp fragment in AA homozygous individuals, three 
fragments 183bp, 108bp and 75bp in AG hetero-
zygous individuals and 108bp and 75bp fragments in 
GG homozygous individuals. 
The region of the TNF-R2 gene containing 
the +676 position was amplified using the primers 
(0.25µM) forward: 5’- TTC TGG AGT TGG CTG 
CGT GT-3’; reverse: 5’- ACT CTC CTA TCC TGC 
CTG CT-3’. A 242 bp PCR product was generated us-
ing the following amplification conditions: 94˚C for 
3 min, followed by 35 cycles at 94˚C for 60 s, 58˚C for 
60 s and 72˚C for 60 s, with a final extension step at 
72˚C for 10 min. Restriction analysis was performed 
using Hin1II restriction enzyme (MBI Fermentas, 
Lithuania). Digestion was performed at 37˚C over-
night (1 unit Hin1II and 10 μl PCR products). The 
genotypes were then assessed by PAA gel electro-
phoresis. The fragments were as follows: 134 bp and 
108 bp fragments in TT homozygous individuals, 
three fragments 242bp, 134bp and 108bp in TG het-
erozygous individuals and a 242 bp fragment in GG 
homozygous individuals. 
For all three polymorphisms, genotypes were 
confirmed by randomly re-genotyping 10% of sam-
ples. There were no discrepancies between genotypes 
determined in duplicate.
Statistical analysis
The Chi square test and Fisher exact test were used to 
determine possible differences in the genotype and 
allele frequencies. The association of all three gene 
variants with risk of disease was examined by uncon-
ditional logistic regression analysis to calculate odds 
ratios (OR) and their 95% confidence intervals (CI). 
P values of <0.05 were considered statistically signifi-
cant. The expected frequency of variants in controls 
was analyzed by the Hardy-Weinberg equilibrium 
test. Calculations were performed using SPSS 10.0 
statistical software (SPSS Inc, Chicago, IL, USA).
RESULTS
No statistically significant difference in genotype 
and allele distribution between patients and controls 
could be observed for TNF-alpha and TNF-R1 poly-
morphisms. However, a difference in genotype and 
allele frequencies was found between patients and 
controls for the TNF-R2 polymorphism. Interest-
ingly, for both OSCC and BCC, the SNP at position 
+676 of the TNF-R2 gene represented a risk factor 
for tumor development. The observed genotype and 
allele frequency distribution and risk estimates for 
polymorphisms in TNF-alpha, TNF-R1 and TNF-R2 
genes are given in Tables 1 (OSCC) and 2 (BCC).
 DISCUSSION
There are only a few reports on the possible asso-
ciation of polymorphisms in inflammatory cytokine 
genes with head and neck cancer, and they mostly 
concern polymorphisms in interleukin genes. Poly-
morphism analyses of tumor necrosis factor and/or 
corresponding receptor genes (TNF-R1 and TNF-
R2) are relatively scarce and mainly involve Asian 
populations (Liu et al., 2005; Gupta et al., 2008; Yang 
et al., 2011). 
Though TNF-alpha gene polymorphisms have 
been widely studied in various non-malignant and 
malignant diseases, we found only two studies re-
cently published dealing with TNF-alpha SNP at 
position -308 as the susceptibility factor for HN-
SCC development (Correa et al., 2011; Yapijakis et 
al., 2009). Correa et al. (2011) demonstrated that the 
-308 allele A and genotype AA in HNSCC individu-
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als might contribute to the higher clinical aggressive-
ness of malignant disease in the Brazilian population. 
Similarly, Yapijakis et al. (2009) showed a strong as-
sociation of TNF-alpha high expression alleles with 
an increased risk of oral cancer. Though TNF-alpha 
(-308G>A) is a functional polymorphism that influ-
ences TNF-alpha gene transcription and thus the 
plasma levels of TNF-alpha, in the present study no 
difference in allele and genotype distribution could 
be established between cancer patients and controls, 
excluding this SNP as a potential risk factor for OS-
CCs in the Serbian population. Since several lines 
of evidence suggest that an increased expression of 
TNF-alpha, upregulated by UV exposure, may con-
tribute to tumor escape from the immune response, 
it seemed reasonable to expect some influence of 
this SNP on BCC development, as found by Skov et 
al. (2003). However, our study did not establish any 
difference in genotype or allele frequencies between 
BCCs and controls. 
The majority of TNF-alpha biological effects are 
initiated through TNF-R1 (TNFRSF1A), and though 
the SNP (36G>A) causes only a silent mutation 
(pro12pro), it may influence mRNA splicing and its 
cellular localization, resulting in different receptor 
Table 1. Genotype and allele frequencies and logistic regression analysis data for the TNF-alpha (-308G>A), TNF-R1 (36A>G) and 
TNF-R2 (676T>G) polymorphisms in OSCC
OSCC
(n=50) control (n=60) OR 95% CI P
    TNF-alpha (-308G>A)
G/G 35 (69%) 39 (65%) 1.00 Reference
G/A 14 (29%) 21 (35%) 0.74 0.33-1.68 0.306
A/A 1   (2%) 0   (0%)
G/A+A/A 15 (31%) 21 (35%) 0.80 0.36-1.78 0.363
G 0.84 0.83 1.00 Reference
A 0.16 0.17 0.93 0.44-1.96 0.500
TNF-R1 (36A>G)
A/A 14 (29%) 21 (35%) 1.00 Reference
A/G 35 (69%) 31 (52%) 1.69 0.74-3.89 0.150
G/G 1   (2%) 8   (13%) 0.19 0.02-1.67 0.105
A/G+G/G 36 (71%) 39 (55%) 1.38 0.6120-R1 0.282
A 0.64 0.61 1.00 Reference
G 0.36 0.39 0.88 0.50-1.56 0.385
 TNF-R2 (676T>G)
T/T 16 (32%) 32 (53%) 1.00 Reference
T/G 33 (65%) 25 (42%) 2.64 1.19-5.84 0.013*
G/G 1    (3%) 3   (5%) 0.67 0.06-6.93 0.604
T/G+G/G 34 (68%) 28 (47%) 2.43 1.11-5.30 0.020*
T 0.65 0.74 1.00 Reference
G 0.35 0.26 1.53 0.84-2.81 0.110
OR – odds ratio; CI – confidence interval
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function. One study showed the interaction of this 
polymorphism with gastroesophageal reflux disease 
that influences the risk of esophageal carcinoma (Wu 
et al., 2011). In our study, no association between a 
given genotype at position +36 and head and neck 
cancer risk could be established.
Binding at TNF-R2 (TNFRSF1B) induces apop-
tosis among CD8+ cells, stimulates the proliferation 
of hematopoietic cells, and potentiates the effects 
of TNF at TNF-R1 (Zheng et al., 1995; MacEwan, 
2002; Tartaglia et al., 1993). Exon 6 codes for a part 
of the TNF-R2 transmembrane domain and the site 
of proteolytic cleavage, resulting in the generation 
of soluble TNF-R2 (sTNFRII) (Zheng et al., 1995). 
The polymorphism (676T>G) in exon 6 of TNF-R2 
causes the replacement of methionine with arginine 
at position 196 (M196R) and may potentially modu-
late the biological effects of TNF since it is located 
within one of four cysteine-rich domains (CRD) that 
are important for optimal TNF binding (Morita et 
al., 2001). In the present study, a significant differ-
ence was found in the distribution of allele and geno-
type frequencies between cases and controls. The as-
Table 2. Genotype and allele frequencies and logistic regression analysis data for the TNF-alpha (-308G>A), TNF-R1 (36A>G) and 
TNF-R2 (676T>G) polymorphisms in BCC
BCC (n=50) control (n=60) OR 95% CI P
    TNF-alpha (-308G>A)
G/G 29 (58%) 39 (65%) 1.00 Reference
G/A 21 (42%) 21 (35%) 1.34 0.62-2.91 0.289
A/A 0   (0%) 0   (0%)
G/A+A/A 21 (42%) 21 (35%) 1.34 0.62-2.91 0.289
G 0.79 0.83 1.00 Reference
A 0.21 0.17 1.30 0.64-2.64 0.295
      
TNF-R1 (36A>G)  
A/A 19 (38%) 21 (35%) 1.00 Reference
A/G 29 (58%) 31 (52%) 1.03 0.46-2.30 0.549
G/G 2   (4%) 8   (13%) 0.28 0.05-1.47 0.110
A/G+G/G 31 (62%) 39 (56%) 0.88 0.40-1.92 0.450
A 0.67 0.61 1.00 Reference
G 0.33 0.39 0.77 0.43-1.37 0.231
       
TNF-R2 (676T>G)
T/T 10 (20%) 32 (53%) 1.00 Reference
T/G 38 (76%) 25 (42%) 4.86 2.04-11.62 <0.001*
G/G 2   (4%) 3   (5%) 2.13 0.31-14.62 0.379
T/G+G/G 40 (80%) 28 (47%) 4.57 1.94-10.79 <0.001*
T 0.58 0.74 1.00 Reference
G 0.42 0.26 2.06 1.13-3.75 0.012*
OR – odds ratio; CI – confidence interval
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sociation between TNF-R2 (676T>G) heterozygous 
genotype and both OSCC and BCC was statistically 
significant (OR 2.52; CI 1.13-5.61, p=0.018 and OR 
4.67: CI 1.92-11.33, p<0.001, respectively). Carriers 
of the G allele have an increased risk of developing 
both oral and skin cancers. Previously, one study 
showed an association between this SNP and breast 
cancer onset (Mestiri et al., 2005) and another found 
association between the SNP and survival in lung 
cancer (Guan et al., 2011). 
Our results suggest that the TNF-R2 gene con-
tributes to a susceptibility to head and neck tumors, 
and that its aberrant expression or function could be 
involved in the development of those tumors. To the 
best of our knowledge, this is the first and unique 
study to deal with TNF-R2 (676T>G) polymorphism 
in head and neck malignancies and which establishes 
the importance of this SNP as a risk factor modula-
tor for two types of tumors with remarkably different 
biology, OSCCs and BCCs.
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